

CORRECTION

Open Access



Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

Lori J. Goldstein¹, Raymond P. Perez^{2,3}, Denise Yardley^{4,10}, Linda K. Han^{5,6}, James M. Reuben⁷, Hui Gao⁷, Susan McCanna⁸, Beth Butler⁸, Pier Adelchi Ruffini⁸, Yi Liu⁹, Roberto R. Rosato⁹ and Jenny C. Chang^{9*}

Correction to: *Breast Cancer Res* (2020) 22:4
<https://doi.org/10.1186/s13058-019-1243-8>

After publication of the original article [1], the authors identified two errors in the Author details:

1. Sarah Cannon Research Institute, Nashville, TN, should be added to Dr. Yardley's affiliation in addition to Tennessee Oncology.
2. Dr. Yardley has provided services to multiple companies on behalf of Sarah Cannon Research Institute.

Author details

¹Department of Medical Oncology, The Hospital of Fox Chase Cancer Center, Philadelphia, PA, USA. ²University of Kansas Medical Research Center, Fairway, KS, USA. ³Current address: Early Oncology Development, Bristol-Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ 08648, USA. ⁴Tennessee Oncology, Nashville, TN, USA. ⁵Indiana University Simon Cancer Center, Indianapolis, IN, USA. ⁶Current address: Parkview Cancer Institute, 11141 Parkview Plaza, Suite 305A, Fort Wayne, IN 46845, USA. ⁷Department of Hematopathology-Research, MD Anderson Cancer Center, Houston, TX, USA. ⁸Research and Development, Dompé farmaceutici S.p.A., 20122 Milan, Italy. ⁹The Methodist Hospital Research Institute, 6445 Main Street, Houston, TX 77030, USA. ¹⁰Sarah Cannon Research Institute, 250 25th Avenue North Suite 200, Nashville, TN 37203, USA.

Published online: 20 May 2020

Reference

1. Goldstein LJ, et al. A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer. *Breast Cancer Res*. 2020; 22:4. <https://doi.org/10.1186/s13058-019-1243-8>.

The original article can be found online at <https://doi.org/10.1186/s13058-019-1243-8>.

* Correspondence: jcchang@houstonmethodist.org

⁹The Methodist Hospital Research Institute, 6445 Main Street, Houston, TX 77030, USA



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.